Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing

Core Insights - Boxer Capital Management, LLC disclosed a purchase of 1,104,734 shares of Tango Therapeutics, with an estimated transaction value of $9.52 million based on average quarterly pricing [1][2] - The acquisition increased Boxer Capital's stake in Tango Therapeutics to 21.09% of its 13F reportable AUM as of December 31, 2025 [3] - Tango Therapeutics shares were priced at $12.80 as of February 17, 2026, reflecting a 426.7% increase over the past year, significantly outperforming the S&P 500 by 406.30 percentage points [3] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing targeted cancer therapies using synthetic lethality [5][6] - The company has a strategic collaboration with Gilead Sciences for the development and commercialization of cancer therapies [6] - Tango Therapeutics targets genetically defined cancers and emphasizes precision medicine in its approach [7] Financial Metrics - As of February 17, 2026, Tango Therapeutics had a market capitalization of $1.41 billion, with a revenue of $66.50 million and a net income of -$100.52 million (TTM) [3]